A carregar...
Dapagliflozin: an evidence-based review of its potential in the treatment of type-2 diabetes
Dapagliflozin is a sodium-glucose co-transporter-2 inhibitor that lowers plasma glucose by decreasing its renal reabsorption. The resulting excretion of glucose in the urine (glucosuria) has transformed what was once solely regarded as an adverse facet of diabetes into a potential novel therapeutic...
Na minha lista:
| Autor principal: | |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2012
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3373192/ https://ncbi.nlm.nih.gov/pubmed/22701099 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CE.S16359 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|